<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04044690</url>
  </required_header>
  <id_info>
    <org_study_id>IgPro20_3007</org_study_id>
    <secondary_id>2018-003171-35</secondary_id>
    <nct_id>NCT04044690</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)</brief_title>
  <acronym>RECLAIIM</acronym>
  <official_title>A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults With Dermatomyositis (DM) - The RECLAIIM Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20&#xD;
      (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). The primary&#xD;
      objective of this study is to assess the efficacy of IgPro20 subcutaneous (SC) doses in&#xD;
      comparison to placebo in adult subjects with DM, as measured by responder status based on&#xD;
      Total Improvement Score (TIS) assessments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2019</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder Rate</measure>
    <time_frame>Weeks 17, 21, and 25</time_frame>
    <description>A responder is defined as a subject with a total improvement score (TIS) ≥ 20 points at Week 25 and at least 1 of the previous scheduled visits (Week 17 or Week 21), who completes 24 weeks of randomized investigational medicinal product (IMP) treatment without the use of rescue corticosteroid treatment. The TIS is a sum response criterion which incorporates 6 weighted IMACS core set measures (CSMs). Thresholds for minimal, moderate, and major improvement were ≥ 20, ≥ 40, and ≥ 60 points on the TIS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Total Improvement Score (TIS)</measure>
    <time_frame>Up to Week 25</time_frame>
    <description>The TIS is a sum response criterion which incorporates 6 weighted IMACS core set measures (CSMs). A total improvement score (range 0 to 100), determined by summing scores for each CSM, was based on improvement in and relative weight of each CSM. Thresholds for minimal, moderate, and major improvement were ≥ 20, ≥ 40, and ≥ 60 points on the TIS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean difference (IgPro20 minus placebo) in TIS</measure>
    <time_frame>Up to week 25</time_frame>
    <description>The TIS is a sum response criterion which incorporates 6 weighted IMACS core set measures (CSMs). A total improvement score (range 0 to 100), determined by summing scores for each CSM, was based on improvement in and relative weight of each CSM. Thresholds for minimal, moderate, and major improvement were ≥ 20, ≥ 40, and ≥ 60 points on the TIS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes from Baseline in Manual Muscle Testing (MMT-8)</measure>
    <time_frame>Up to week 25</time_frame>
    <description>MMT-8 is a set of 8 designated muscles which will be tested bilaterally (potential score 0 to 150): 7 biaxial muscles with potential score 0 to140 and 1 axial (neck flexors) with potential score 0 to10. Improvement is documented with an increase in score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change difference (IgPro20 minus placebo) in MMT-8</measure>
    <time_frame>Up to week 25</time_frame>
    <description>MMT-8 is a set of 8 designated muscles which will be tested bilaterally (potential score 0 to 150): 7 biaxial muscles with potential score 0 to140 and 1 axial (neck flexors) with potential score 0 to10. Improvement is documented with an increase in score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes from Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) total activity score</measure>
    <time_frame>Up to week 25</time_frame>
    <description>The CDASI in its modified version (v2) is a validated tool of skin disease activity (3 items) and damage (3 items) assessment. Scores range from 0-100 for activity and from 0-32 for damage. Improvement is documented with a decrease in score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change difference (IgPro20 minus placebo) in CDASI</measure>
    <time_frame>Up to week 25</time_frame>
    <description>The CDASI in its modified version (v2) is a validated tool of skin disease activity (3 items) and damage (3 items) assessment. Scores range from 0-100 for activity and from 0-32 for damage. Improvement is documented with a decrease in score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean TIS</measure>
    <time_frame>Week 5 up to Week 53</time_frame>
    <description>The TIS is a sum response criterion which incorporates 6 weighted IMACS core set measures (CSMs). A total improvement score (range 0 to 100), determined by summing scores for each CSM, was based on improvement in and relative weight of each CSM. Thresholds for minimal, moderate, and major improvement were ≥ 20, ≥ 40, and ≥ 60 points on the TIS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving TIS ≥ 20, ≥ 40, and ≥ 60 points</measure>
    <time_frame>Week 5 up to Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first achieving TIS ≥ 20, ≥ 40, and ≥ 60 points on the TIS</measure>
    <time_frame>Week 5 up to Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving TIS ≥ 20 points at the end of study period 2</measure>
    <time_frame>Up to week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes from baseline in individual CSMs (except muscle enzymes) and CDASI</measure>
    <time_frame>Between Week 5 and Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes in individual CSMs (except muscle enzymes) and CDASI</measure>
    <time_frame>From week 29 to week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects meeting Definition of Worsening (DOW) at least once, twice, or &gt; twice</measure>
    <time_frame>Baseline up to Week 53</time_frame>
    <description>The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart:&#xD;
Physician Global Activity Assessment Visual Analog Scale (VAS) worsening ≥ 2 cm* and Manual Muscle Test (MMT)-8 worsening ≥ absolute 10%, or&#xD;
Extramuscular Global Assessment worsening ≥ 2 cm on the Myositis Disease Activity Assessment Tool (MDAAT) VAS, or&#xD;
Any 3 of 6 CSM worsening by ≥ absolute 20%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects meeting DOW at least once, twice, or &gt; twice</measure>
    <time_frame>Baseline up to Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to meeting DOW for the first time</measure>
    <time_frame>Baseline up to Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects meeting DOW and receiving rescue steroid treatment</measure>
    <time_frame>Baseline up to Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects meeting DOW and receiving rescue steroid treatment</measure>
    <time_frame>Baseline up to Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects receiving rescue steroid treatment</measure>
    <time_frame>Baseline up to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose rescue steroid treatment is tapered</measure>
    <time_frame>Baseline up to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects having at least 1 level, 2 levels, and more than 2 levels of improvement from Baseline in mobility, self-care, and usual activities domains of EuroQoL 5-Dimension Questionnaire (EQ-5D-5L)</measure>
    <time_frame>Baseline up to Week 53</time_frame>
    <description>The subject will select which best describes his own health state at the study visit in the following dimensions: Mobility, Self-care, Usual Activities. The subject will also select a point on a scale drawn like a thermometer to indicate how good or bad the health state is, with best state as &quot;100&quot; and worst state as &quot;0.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects having at least 1 level, 2 levels, and more than 2 levels of improvement from Baseline in mobility, self-care, and usual activities domains of EQ-5D-5L</measure>
    <time_frame>Baseline up to Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects having no reduction in levels, at least 1 level, 2 levels, and more than 2 levels of improvement in mobility, self-care, and usual activities domains of EQ-5D-5L from Week 25</measure>
    <time_frame>From Week 25 up to week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects having no reduction in levels, at least 1 level, 2 levels, and more than 2 levels of improvement in mobility, self-care, and usual activities domains of EQ-5D-5L from Week 25</measure>
    <time_frame>From Week 25 up to week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to week 197</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with related TEAEs</measure>
    <time_frame>Up to week 197</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with serious TEAEs</measure>
    <time_frame>Up to week 197</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of TEAEs per days with infusion</measure>
    <time_frame>Up to week 197</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of TEAEs per days with infusion, by severity</measure>
    <time_frame>Up to week 197</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of related TEAEs per days with infusion</measure>
    <time_frame>Up to week 197</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of serious TEAEs per days with infusion</measure>
    <time_frame>Up to week 197</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who are able to reduce the oral corticosteroid dose by ≥ 25%</measure>
    <time_frame>Up to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who are able to reduce the oral corticosteroid dose by ≥ 25%</measure>
    <time_frame>Up to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The odds ratio (IgPro20:Placebo) of subjects who are able to reduce the oral corticosteroid dose by ≥ 25%</measure>
    <time_frame>Up to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who start oral corticosteroid dose taper</measure>
    <time_frame>Baseline up to Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who start oral corticosteroid dose taper</measure>
    <time_frame>Baseline up to Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who are able to reduce the oral corticosteroid dose by ≥ 25%, ≥ 50%, ≥ 75%</measure>
    <time_frame>Baseline up to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who are able to reduce the oral corticosteroid dose by ≥ 25%, ≥ 50%, ≥ 75%</measure>
    <time_frame>Baseline up to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who are able to reduce the oral corticosteroid dose by ≥ 25%, ≥ 50%, ≥ 75%</measure>
    <time_frame>Baseline up to Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first intake of rescue corticosteroid treatment</measure>
    <time_frame>Baseline up to Week 25</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Dermatomyositis</condition>
  <arm_group>
    <arm_group_label>IgPro20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>human immunoglobulin G administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>human albumin solution administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human immunoglobulin G</intervention_name>
    <description>human immunoglobulin G administered subcutaneously</description>
    <arm_group_label>IgPro20</arm_group_label>
    <other_name>IgPro20</other_name>
    <other_name>Hizentra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>contains 2% human albumin, similar excipients as IgPro20 (Hizentra), same volume, same duration, administered subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects ≥ 18 years of age&#xD;
&#xD;
          -  Diagnosis of at least probable idiopathic inflammatory myopathies (IIM) per European&#xD;
             League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification&#xD;
             Criteria which includes confirmation of dermatomyositis (DM) rash/manifestation,&#xD;
             disease activity defined by presence of DM rash / manifestation or an objective&#xD;
             disease activity measure&#xD;
&#xD;
          -  Disease severity defined by Physician global activity visual analog scale (VAS) with a&#xD;
             minimum value of 2.0 cm on a 10 cm scale and MMT-8 ≤ 142 or CDASI total activity score&#xD;
             ≥ 14.&#xD;
&#xD;
          -  Corticosteroid daily dose less than that or equal to 20 mg prednisolone equivalent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cancer-associated myositis&#xD;
&#xD;
          -  Evidence of active malignant disease or malignancies diagnosed within the previous 5&#xD;
             years&#xD;
&#xD;
          -  Physician Global Damage score ≥ 3, or clinically relevant improvement between&#xD;
             Screening Visit and Baseline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Registration Coordinator</last_name>
    <phone>610-878-4000</phone>
    <email>clinicaltrials@cslbehring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Research</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neuromuscular Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sutter Pacific Medical Foundation FORBES Norris MDA ALS Research and Treatment Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center For Rheumatology</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omega Research Maitland</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida (USF) - Carol and Frank Morsani Center for Advanced Health Care (CAHC)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Missouri Health Care</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health Physicians</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Modern Clinic LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research &amp; Consulting</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wesley Neurology Clinic</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas Medical School at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest Rheumatology Research</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Perron Institute for Neurological and Translational Science</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ghent Universit Hospital (UZ Gent)</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis (UZ) Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Liège - Sart Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU De Dijon Hopital Du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU - Hospital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nice-Hopital Archet I</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Paris Group Hospitalier La Pitie Salpetriere-Charles Foix</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaire de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medicine Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi Di Brescia - Azienda Ospedaliera Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaria Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi Firenze</name>
      <address>
        <city>Firenze</city>
        <zip>5134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Sacred Heart Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chukyo Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>457-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Fukui Hospital</name>
      <address>
        <city>Yoshida-Gun</city>
        <state>Fukui</state>
        <zip>910-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gunma University Hospital</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <zip>371-6511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Marianna University Hospital</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Bunkyo-Ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Hospital</name>
      <address>
        <city>Bunkyō-Ku</city>
        <state>Tokyo</state>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Shinjuku-Ku</city>
        <state>Tokyo</state>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical And Dental University Medical Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University Hospital</name>
      <address>
        <city>Wakayama</city>
        <zip>641-8509</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Hospital</name>
      <address>
        <city>Yamaguchi</city>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CINTRE, Centro de Investigacion y Tratamiento Reumatologico S.C.</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Integral en Reumatologia, SA de CV</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44160</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Alta Especialidad en Reumatologia e Investigacion del Potosí, S.C.</name>
      <address>
        <city>San Luis Potosí</city>
        <zip>78213</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Specjalistyczne Gabinety Sp. z o.o</name>
      <address>
        <city>Krakow</city>
        <zip>30-539</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zespol Poradni Specjalistycznych REUMED, ONYKSOWA Filia nr 2</name>
      <address>
        <city>Lublin</city>
        <zip>20-582</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Grunwald</name>
      <address>
        <city>Poznań</city>
        <zip>60-369</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ORIS Firm Limited Liability Company</name>
      <address>
        <city>Moscow</city>
        <zip>117321</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Medicoprophylactyc Institution</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Centre-Healthy Family</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Petersburg City Rheumatological Hospital 25</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Autonomous Healthcare Institution of Yaroslavl Oblast Clinical Hospital 3</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Cherkasy Regional Hospital of Cherkasy Regional Council</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mechnikov Institute of Microbiology and Immunology of NAMS of Ukraine Kharkiv City Multispecialty Hospital</name>
      <address>
        <city>Kharkiv</city>
        <zip>61029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Khmelnitskiy Regional Hospital</name>
      <address>
        <city>Khmelnytskyi</city>
        <zip>29000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv Railway Clinical Hospital No.2</name>
      <address>
        <city>Kyiv</city>
        <zip>03049</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic of Modern Rheumatology</name>
      <address>
        <city>Kyiv</city>
        <zip>04071</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Modern Clinic LLC</name>
      <address>
        <city>Zaporizhia</city>
        <zip>69005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Doncaster Royal Infirmary</name>
      <address>
        <city>Doncaster</city>
        <zip>DN2 5LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatomyositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.&#xD;
Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.&#xD;
If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.</ipd_time_frame>
    <ipd_access_criteria>Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.&#xD;
An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.&#xD;
The requesting party must execute an appropriate data sharing agreement before IPD will be made available.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

